Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $4.06 in the last session, up 2.01% from day before closing price of $3.98. In other words, the price has increased by $2.01 from its previous closing price. On the day, 3.13 million shares were traded. IRWD stock price reached its highest trading level at $4.145 during the session, while it also had its lowest trading level at $3.87.
Ratios:
We take a closer look at IRWD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.76. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.13.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 05 ’26 when Silver Ronald sold 35,416 shares for $4.60 per share. The transaction valued at 162,914 led to the insider holds 276,809 shares of the business.
RONALD SILVER bought 35,416 shares of IRWD for $151,226 on Jan 05 ’26. On Nov 17 ’25, another insider, Gaskins Tammi L, who serves as the Chief Commercial Officer of the company, sold 6,016 shares for $3.32 each. As a result, the insider received 19,973 and left with 235,264 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 660475264 and an Enterprise Value of 1118308352. As of this moment, Ironwood’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.30, and their Forward P/E ratio for the next fiscal year is 5.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.95. Its current Enterprise Value per Revenue stands at 3.299 whereas that against EBITDA is 7.677.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.17, which has changed by 0.07692313 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.78, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 26.68%, while the 200-Day Moving Average is calculated to be 160.10%.
Shares Statistics:
According to the various share statistics, IRWD traded on average about 4.01M shares per day over the past 3-months and 11807030 shares per day over the past 10 days. A total of 162.68M shares are outstanding, with a floating share count of 156.69M. Insiders hold about 3.68% of the company’s shares, while institutions hold 91.68% stake in the company. Shares short for IRWD as of 1765756800 were 7329764 with a Short Ratio of 1.83, compared to 1763078400 on 7154955. Therefore, it implies a Short% of Shares Outstanding of 7329764 and a Short% of Float of 6.819999999999999.
Earnings Estimates
A detailed examination of Ironwood Pharmaceuticals Inc (IRWD) is currently in progress, with 2.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.15, with high estimates of $0.19 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.26 and $0.25 for the fiscal current year, implying an average EPS of $0.25. EPS for the following year is $0.85, with 3.0 analysts recommending between $1.1 and $0.41.
Revenue Estimates
According to 3 analysts,. The current quarter’s revenue is expected to be $50.93M. It ranges from a high estimate of $57.7M to a low estimate of $47.1M. As of. The current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $90.55MFor the next quarter, 3 analysts are estimating revenue of $86.1M. There is a high estimate of $97.2M for the next quarter, whereas the lowest estimate is $75M.
A total of 3 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $306.2M, while the lowest revenue estimate was $295.5M, resulting in an average revenue estimate of $299.23M. In the same quarter a year ago, actual revenue was $351.41MBased on 3 analysts’ estimates, the company’s revenue will be $410.5M in the next fiscal year. The high estimate is $461.6M and the low estimate is $310.2M.
